Accéder au contenu
Merck
Toutes les photos(2)

Documents

T7947

Sigma-Aldrich

(R)-Tomoxetine hydrochloride

solid

Synonyme(s) :

(R)-N-Methyl-γ-(2-methyl­phenoxy)benzenepropanamine hydrochloride, Atomoxetine hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C17H21NO · HCl
Numéro CAS:
82248-59-7
Poids moléculaire :
291.82
Numéro MDL:
MFCD06410992
Code UNSPSC :
12352200
ID de substance PubChem :
24278760
Nomenclature NACRES :
NA.77

Forme

solid

Auteur

Eli Lilly

Température de stockage

2-8°C

Chaîne SMILES 

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

Clé InChI

LUCXVPAZUDVVBT-UNTBIKODSA-N

Informations sur le gène

human ... SLC6A2(6530)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
  • to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
  • to study its effects on set shifting in rats
  • to study its effects on rat brain as a result of its long-term use

Actions biochimiques/physiologiques

(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters. It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC). (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter. It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
Norepinephrine uptake blocker.

Caractéristiques et avantages

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Grazia Dell'Agnello et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 19(11), 822-834 (2009-09-01)
The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. This was
Fatma Gür et al.
Biochemical and biophysical research communications, 534, 927-932 (2020-11-05)
Attention Deficit Hyperactivity Disorder (ADHD) is the most common psychiatric disorder reported particularly in children. Long-term use of antipsychotic drugs used in the treatment of ADHD has been shown to exert toxic effects on the brain. However, not enough research
Chi-Yung Shang et al.
Journal of child and adolescent psychopharmacology, 22(5), 353-363 (2012-10-23)
Atomoxetine is efficacious in reducing symptoms of attention- deficit/hyperactivity disorder (ADHD), but its effect on visual memory and attention needs more investigation. This study aimed to assess the effect of atomoxetine on visual memory, attention, and school function in boys
Nora D Volkow et al.
The New England journal of medicine, 369(20), 1935-1944 (2013-11-15)
Short-term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long-term benefits and risks of these medications, particularly among older persons, have been insufficient.
Wolfgang Retz et al.
Expert review of neurotherapeutics, 12(10), 1241-1251 (2012-10-23)
Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of inattention, hyperactivity and impulsivity. There is an ongoing discussion whether symptoms of emotional dysregulation should be added to the conceptualization of ADHD in order to describe the
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique